Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Alzheimer's disease drug development pipeline: 2023
Jeffrey L. Cummings, Yadi Zhou, Garam Lee, et al.
Alzheimer s & Dementia Translational Research & Clinical Interventions (2023) Vol. 9, Iss. 2
Open Access | Times Cited: 321

Showing 1-25 of 321 citing articles:

<p>Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics</p>
Sneham Tiwari, Venkata Atluri, Ajeet Kaushik, et al.
International Journal of Nanomedicine (2019) Vol. Volume 14, pp. 5541-5554
Open Access | Times Cited: 965
2024 Alzheimer's disease facts and figures

Alzheimer s & Dementia (2024) Vol. 20, Iss. 5, pp. 3708-3821
Open Access | Times Cited: 544
Diagnosis of Early Alzheimer’s Disease: Clinical Practice in 2021
Anton P. Porsteinsson, Richard Isaacson, S. Knox, et al.
The Journal of Prevention of Alzheimer s Disease (2021), pp. 1-16
Open Access | Times Cited: 382
MULTIDOMAIN INTERVENTIONS TO PREVENT COGNITIVE IMPAIRMENT, ALZHEIMER’S DISEASE, AND DEMENTIA: FROM FINGER TO WORLD-WIDE FINGERS
Anna Rosenberg, Francesca Mangialasche, Tiia Ngandu, et al.
The Journal of Prevention of Alzheimer s Disease (2019), pp. 1-8
Open Access | Times Cited: 223
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
Jeffrey L. Cummings, Amanda M. Leisgang Osse, Davis Cammann, et al.
BioDrugs (2023) Vol. 38, Iss. 1, pp. 5-22
Open Access | Times Cited: 116
Accelerating Alzheimer’s therapeutic development: The past and future of clinical trials
Adam L. Boxer, Reisa A. Sperling
Cell (2023) Vol. 186, Iss. 22, pp. 4757-4772
Open Access | Times Cited: 71
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification
Jeffrey L. Cummings, Amanda M. Leisgang Osse, Jefferson W. Kinney
Drugs (2023) Vol. 83, Iss. 15, pp. 1387-1408
Open Access | Times Cited: 63
Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies
Francesca R. Buccellato, Marianna D’Anca, Gianluca Martino Tartaglia, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 13900-13900
Open Access | Times Cited: 45
The six brain‐specific TAU isoforms and their role in Alzheimer's disease and related neurodegenerative dementia syndromes
Sarah Buchholz, Hans Zempel
Alzheimer s & Dementia (2024) Vol. 20, Iss. 5, pp. 3606-3628
Open Access | Times Cited: 19
Alzheimer’s disease: insights into pathology, molecular mechanisms, and therapy
Qiuyang Zheng, Xin Wang
Protein & Cell (2024)
Open Access | Times Cited: 19
Treatment of Alzheimer Disease
David Geldmacher
CONTINUUM Lifelong Learning in Neurology (2024) Vol. 30, Iss. 6, pp. 1823-1844
Closed Access | Times Cited: 19
Artificial intelligence and open science in discovery of disease-modifying medicines for Alzheimer’s disease
Feixiong Cheng, Fei Wang, Jian Tang, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 2, pp. 101379-101379
Open Access | Times Cited: 18
The 2022 symposium on dementia and brain aging in low‐ and middle‐income countries: Highlights on research, diagnosis, care, and impact
Raj N. Kalaria, Gladys E. Maestre, Simin Mahinrad, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 6, pp. 4290-4314
Open Access | Times Cited: 15
Second-generation anti-amyloid monoclonal antibodies for Alzheimer’s disease: current landscape and future perspectives
Byeong‐Hyeon Kim, Sujin Kim, Yunkwon Nam, et al.
Translational Neurodegeneration (2025) Vol. 14, Iss. 1
Open Access | Times Cited: 4
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease
Jeffrey L. Cummings, Alireza Atri, Howard Feldman, et al.
Alzheimer s Research & Therapy (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 3
DeepDrug as an expert guided and AI driven drug repurposing methodology for selecting the lead combination of drugs for Alzheimer’s disease
Victor O. K. Li, Yang Han, Tushar Kaistha, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 2
RATIONALE FOR EARLY DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT (MCI) SUPPORTED BY EMERGING DIGITAL TECHNOLOGIES
Marwan N. Sabbagh, Merçé Boada, Soo Borson, et al.
The Journal of Prevention of Alzheimer s Disease (2020), pp. 1-7
Open Access | Times Cited: 71
The Role of Glial Cells in Synaptic Dysfunction: Insights into Alzheimer's Disease Mechanisms
Yang Yu, Ran Chen, Kaiyue Mao, et al.
Aging and Disease (2023) Vol. 15, Iss. 2, pp. 459-459
Open Access | Times Cited: 22
Numerical and Analytical Simulation of the Growth of Amyloid-β Plaques
A. V. Kuznetsov
Journal of Biomechanical Engineering (2024) Vol. 146, Iss. 6
Open Access | Times Cited: 12
Mechanistic insights and emerging therapeutic stratagems for Alzheimer’s disease
Kayalvizhi Rajendran, Uma Maheswari Krishnan
Ageing Research Reviews (2024) Vol. 97, pp. 102309-102309
Closed Access | Times Cited: 12
The Enigma of Tau Protein Aggregation: Mechanistic Insights and Future Challenges
Huiting Zheng, Huimin Sun, Qixu Cai, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 9, pp. 4969-4969
Open Access | Times Cited: 12
Neuroimaging and fluid biomarkers in Parkinson’s disease in an era of targeted interventions
Angeliki Zarkali, George E. Thomas, Henrik Zetterberg, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 12
CoQ10 and Mitochondrial Dysfunction in Alzheimer’s Disease
Zdeněk Fišar, Jana Hroudová
Antioxidants (2024) Vol. 13, Iss. 2, pp. 191-191
Open Access | Times Cited: 11
CSF protein ratios with enhanced potential to reflect Alzheimer’s disease pathology and neurodegeneration
Sára Mravinacová, Vilma Alanko, Sofia Bergström, et al.
Molecular Neurodegeneration (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top